Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Q32 Bio (QTTB) EBITDA (2018 - 2025)

Historic EBITDA for Q32 Bio (QTTB) over the last 8 years, with Q3 2025 value amounting to -$7.6 million.

  • Q32 Bio's EBITDA rose 5972.68% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year increase of 4378.5%. This contributed to the annual value of -$66.1 million for FY2024, which is 3698.48% down from last year.
  • As of Q3 2025, Q32 Bio's EBITDA stood at -$7.6 million, which was up 5972.68% from -$9.2 million recorded in Q2 2025.
  • Q32 Bio's EBITDA's 5-year high stood at -$1.1 million during Q1 2021, with a 5-year trough of -$37.6 million in Q1 2022.
  • For the 5-year period, Q32 Bio's EBITDA averaged around -$19.6 million, with its median value being -$17.9 million (2024).
  • As far as peak fluctuations go, Q32 Bio's EBITDA surged by 9695.55% in 2021, and later tumbled by 328595.86% in 2022.
  • Quarter analysis of 5 years shows Q32 Bio's EBITDA stood at -$33.6 million in 2021, then decreased by 2.58% to -$34.5 million in 2022, then increased by 25.18% to -$25.8 million in 2023, then skyrocketed by 43.72% to -$14.5 million in 2024, then surged by 47.84% to -$7.6 million in 2025.
  • Its last three reported values are -$7.6 million in Q3 2025, -$9.2 million for Q2 2025, and -$12.2 million during Q1 2025.